Vytrus Biotech, S.A. (BME:VYT)

Market Cap	124.40M +401.0%
Revenue (ttm)	9.69M +59.1%
Net Income	2.90M +183.7%
EPS	0.39 +184.0%
Shares Out	7.52M
PE Ratio	42.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,977
Open	16.60
Previous Close	16.45
Day's Range	16.20 - 16.60
52-Week Range	3.70 - 20.60
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 9, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 44
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: VYT

Financial Performance

In 2025, Vytrus Biotech's revenue was 9.69 million, an increase of 59.15% compared to the previous year's 6.09 million. Earnings were 2.90 million, an increase of 183.70%.